Replies to post #7442 on Cellectar Biosciences Inc (CLRB)

[Rymankoly]

If trial results are good, 2019 might be a breakout year.
But we need full P2 data on many more patients and they need money for that.
At current cash position, they can't really negotiate....
I'm not sure what the outcome will be, but I don't think they can do it on their own.